Trials / Completed
CompletedNCT01457560
Immunogenicity and Reactogenicity of DTPa-HBV-IPV/Hib Vaccine Followed by the Same Vaccine and Oral Polio Vaccine
Study to Assess the Immunogenicity and Reactogenicity of DTPa-HBV-IPV Mixed With Hib Vaccine in Healthy Infants, Followed by a Dose of the Same Vaccine Administered Simultaneously With One Dose of Oral Polio Vaccine (OPV)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 80 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 12 Weeks – 16 Weeks
- Healthy volunteers
- Accepted
Summary
This study will assess the immunogenicity and safety of the GlaxoSmithKline (GSK) Biologicals' (formerly SmithKline Beecham Biologicals') combined DTPa-HBV-IPV/Hib (Infanrix hexa™) vaccine administered in the 3rd, 5th, 11th month of life. The last dose of DTPa-HBV-IPV/Hib will be given simultaneously with one dose of OPV vaccine.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | DTPa-HBV-IPV/Hib (Infanrix hexa™) | Three doses administered intramuscularly |
| BIOLOGICAL | OPV | One dose administered orally |
Timeline
- Start date
- 2000-02-01
- Primary completion
- 2001-04-01
- Completion
- 2001-04-01
- First posted
- 2011-10-24
- Last updated
- 2016-08-05
Source: ClinicalTrials.gov record NCT01457560. Inclusion in this directory is not an endorsement.